Drugs / anti-CEA CAR-T cells
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05240950 | Aug 2022 → Dec 2023 overdue | metastasis from malignant tumor of colon | Changhai Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT03682744 | Sep 2018 → Dec 2020 | breast cancer, colorectal cancer, gastric cancer, malignant pancreatic neoplasm +1 | Sorrento Therapeutics, Inc. | Withdrawn | No outcome recorded |
| Phase 1 | NCT02416466 | Apr 2015 → Nov 2016 | — | Roger Williams Medical Center | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04037241 | Nov 2021 → Jan 2022 | malignant pancreatic neoplasm | Sorrento Therapeutics, Inc. | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-CEA CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03682744 ↗ |
| Modality | Cell therapy | “T cells are activated and then re-engineered to express chimeric antigen receptors (CARs) specific for CEA.” NCT02416466 ↗ |
| Route | Other | “returned to the patient by percutaneous hepatic artery infusion” NCT02416466 ↗ |